HEOR & Economic Modeling

Undiagnosed and Undertreated Sleep Apnea Costs U.S. Employers More Than $180 Billion Annually

George Padron
Cost-Effective Analysis, Real World Evidence, HEOR & Economic Modeling, Respiratory & Pulmonary Care | Mar 14, 2026
A study estimates OSA syndrome costs U.S. employers over $180 billion yearly in productivity losses, making the case for broader screening and CPAP coverage.

Pharmaceutical Giant's Vaccine Acquisition Positions Adult Immunization Portfolio for Formulary Competition

George Padron
Healthcare Headlines, HEOR & Economic Modeling | Jan 4, 2026
Sanofi's acquisition of Dynavax for $2.2 billion adds differentiated adult vaccines to portfolio, creating new formulary considerations for managed care organizations.

Managed Care Implications of CDC Vaccine Policy Shift on Hepatitis B Birth Dose

George Padron
Medicare/Medicaid Updates, Pediatric Vaccine Updates, Healthcare Headlines, Policy & Legislation, HEOR & Economic Modeling, Coverage Navigation Strategies | Dec 7, 2025
Federal advisers voted to end the universal hepatitis B birth dose, introducing a shared decision-making framework that complicates coverage and delivery systems.

FDA Announces Major Shifts in Vaccine Approval Standards

George Padron
State & Federal Regulations, Pediatric Vaccine Updates, Policy & Legislation, HEOR & Economic Modeling | Dec 4, 2025
FDA announces significant shifts in vaccine approval processes, requiring larger clinical trials and revised evaluation frameworks for respiratory immunizations.

Pharmaceutical Companies Navigate Targeted COVID Vaccine Market Amid Policy Shift

George Padron
State & Federal Regulations, Real World Evidence, Healthcare Headlines, HEOR & Economic Modeling | Aug 30, 2025
Pfizer, Moderna, and Novavax gain FDA approval for updated COVID vaccines limited to 65+ and high-risk patients, changing industry market dynamics